2024
Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
Li R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, Brausi M, Bree K, Fernández M, Guo C, Horowitz A, Lamm D, Lerner S, Lotan Y, Mariappan P, McConkey D, Mertens L, Mir C, Ross J, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess P, Svatek R, Tan W, Taoka R, Buckley R, Kamat A. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. European Urology 2024 PMID: 39183090, DOI: 10.1016/j.eururo.2024.08.001.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder-sparing treatmentCarcinoma in situNadofaragene firadenovecRadical cystectomyBladder cancerOptimal selection of patientsAbsence of randomized trialsBladder-sparing therapySingle-agent chemotherapyBladder cancer groupSelection of patientsDevelopment of agentsPatient selectionSystemic toxicityCancer groupUnapproved agentsClinical trial participationPatient characteristicsRandomized trialsMitomycin CTumor attributesConsensus recommendationsCancer experts
2023
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
Tan W, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo C, Nogueras-Gonzalez G, Navai N, Dinney C, Kamat A. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. European Urology Open Science 2023, 53: 16-22. PMID: 37441349, PMCID: PMC10334230, DOI: 10.1016/j.euros.2023.04.013.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerBladder-sparing treatmentLong-term survival outcomesCancer-specific survivalBCG-unresponsive NMIBC patientsEarly radical cystectomyRadical cystectomySurvival outcomesOverall survivalBladder cancerDelayed RCNMIBC patientsEarly RCAnalysis of long-term survival outcomesHigh-grade recurrenceProgression-free rateRecurrence-free rateMedian follow-upShort-term outcomesLong-term outcomesCurrent smoker statusCT1 diseaseLymphovascular invasionVariant histologyPrimary endpoint